.png){kind=icon}
.png){kind=icon}
Return
Nucleotide-Derived Competitive Inhibitors of Ectonucleotidase CD39─A Promising Extracellular Target for Immunotherapy of Cancer
.png){kind=icon}
OA
AI
C
F
L
S
H
P
C
R
R
G
J
L
J
L
H
G
V
A
L
K
J
E
A
C
DOI：10.1021/acs.jmedchem.6c00054.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Ectonucleotidases catalyze the hydrolysis of extracellular nucleotides, maintaining the balance between proinflammatory ATP and immunosuppressive adenosine. In the present study, we developed potent competitive inhibitors of the main ATP-hydrolyzing ectoenzyme nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, CD39) based on 8-butylthio-AMP as a lead structure. Altogether, 88 purine nucleotides and analogs with broad structural modifications were synthesized, 78 of which are new compounds. 8-Substitution of the purine scaffold with bulky residues is essential for high potency and confers metabolic stability. 8-(1-Naphthylthio)-N6-(4-phenylbutyl)-AMP (42b, PSB-24379) is the most potent CD39 inhibitor of the series (Ki 77.4 nM), showing ancillary CD73 inhibition (Ki 240 nM). Docking into a human CD39 homology model rationalized key interactions. PSB-24379 reduced ATP hydrolysis in melanoma and breast cancer cell membranes and partially reverted ATP-mediated effects on T cell activation and proliferation in an ATP-rich environment. These CD39 inhibitors represent high-quality tool compounds with potential as drugs for immunotherapy of cancer.
Keywords:
Inhibitors
Nuclear magnetic resonance spectroscopy
Nucleic acids
Reaction products
Journal
IF:
6.8
Papers:
2.7W
Citations:
9.4W
Organization
Cited Papers